Clinical trial, funded partly by the Belgian Charcot Foundation, for RRMS patients currently underway through the University in Brussels uses a drug (bosentan) approved to treat arterial cerebral hypertension by relaxing blood vessels. It is hypothesized that patients receiving the drug may show improvements to cerebral blood flow, mitochondrial function, fatigue, cognition, and mobility.

https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3252-4